SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
San Diego-based Aethlon Medical Inc., a company developing targeted therapeutic devices to address infectious diseases and cancer, announced that its majority-owned subsidiary Exosome Sciences Inc. has entered into a research collaboration with Thomas Jefferson University.April 3, 2015 1:04 p.m. Share
MEDICINE: They Can Make Aggressive Cuts, Pursue Other Avenues
Those in the science business must learn to roll with the punches when clinical trials flop, especially when the companies are public, and the failures are broadcast on a global stage, industry veterans said.
Sanford-Burnham Medical Research Institute will collaborate with Eli Lilly and Co. to develop immunological therapies, the companies announced.
Foundry Medical Innovations, a medical and diagnostic device development company in Carlsbad, has merged with Zeis Consulting Group, an IVD clinical research firm.
Cidara Therapeutics Inc. reported May 21 a net loss of $6.7 million for the first quarter of 2015, up from a net loss of $707,000 in the same quarter of last year.
San Diego drug developer Lpath Inc. said it would cut jobs and costs after its experimental eye drug failed a mid-stage study in patients with wet age-related macular degeneration, a leading cause of blindness in the elderly.
Companion Medical Inc., a medical device company in San Diego, has announced the completion of a series B financing, led by an investment from Eli Lilly and Co.
Tandem Diabetes Care Inc., a medical device company in San Diego, announced Tuesday that its t:flex Insulin Pump is on the market, with shipments planned in June.
Sevion Therapeutics Inc., a biopharmaceutical company developing therapies for cancer and immunological diseases, has raised $3.02 million in equity financing according to a recent statement filed with the Securities and Exchange Commission.
Fate Therapeutics, Inc., a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced that it has commenced an underwritten public offering of 6 million shares of its common stock.
Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, announced the appointment of Eric Loumeau as general counsel and chief compliance officer.
The Qualcomm Institute is launching a new innovation space at the University of California, San Diego with the capacity to house 15 to 20 seed-stage startups.
BIOTECH: Deal With Bayer May Be Worth Up to $375 Million
Isis Pharmaceuticals has landed a megadeal with aspirin-maker Bayer AG to move a potential blockbuster drug from the lab to the market.
BIOTECH: Bioprinter Aims to Give L’Oreal Tissue for Product Testing
Organovo has landed a research partnership with beauty conglomerate L’Oreal to create 3-D bioprinted human skin to test cosmetics.
In a deal potentially worth up to $1.3 billion, San Diego’s Sorrento Therapeutics has sold the rights to its proposed cancer treatment Cynviloq, as well as the wholly owned subsidiary that was developing the drug, to Illinois-based NantPharma.
San Diego drug developer Celladon Corp. said it is laying off half of its staff to cut costs after its lead gene therapy to treat heart failure failed a key trial last month.